Company Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products.
The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products.
The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.
Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs.
The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases.
In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.
The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.
InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 1981 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Eric Adams |
Contact Details
Address: 815 West Hastings Street, Suite 310 Vancouver, BC V6C 1B4 Canada | |
| Phone | 604 669 7207 |
| Website | inmedpharma.com |
Stock Details
| Ticker Symbol | INM |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001728328 |
| CUSIP Number | 457637601 |
| ISIN Number | CA4576376012 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Eric A. Adams B.S. Chem., M.I.B. | President, Chief Executive Officer and Director |
| Michael Woudenberg P.Eng. | Chief Operating Officer |
| Alexandra Diane-Janet Mancini M.Sc. | Senior Vice President of Clinical and Regulatory Affairs |
| Dr. Sazzad Hossain M.Sc., Ph.D. | Co-Founder |
| N. Netta Jagpal | Chief Financial Officer and Corporate Secretary |
| Sarah Li CPA, CGA | Vice President of Accounting and Controller |
| Colin Clancy | Senior Director of Investor Relations |
| Jerry P. Griffin | Vice President of Sales and Marketing |
| Dr. Eric Chih-Hsien Hsu | Senior Vice President of Preclinical Research and Development |
| Dr. Shane A. Johnson Ph.D. | Senior Vice President and GM of BayMedica |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 21, 2024 | 8-K | Current Report |
| Aug 20, 2024 | 8-K | Current Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 424B3 | Prospectus |
| Jun 11, 2024 | 8-K | Current Report |
| May 14, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 18, 2024 | 8-K | Current Report |
| Apr 16, 2024 | 8-K | Current Report |